Articles tagged with Acquired Immune Deficiency Syndrome
A UK allied health professor has received a patent to test the effectiveness of combining lithium salts with existing anti-viral drug agents for AIDS patients. The proposed treatment aims to reduce toxic side effects and enhance the immune system, potentially reducing the amount of virus in the body.
A peer-led intervention program, EachOne TeachOne, has shown success in reducing high-risk behaviors among drug users, with 80% of participants cutting back on their drug use or maintaining a low level of risk. However, condom use remained an area of concern, with only 25% of participants showing improvements.
Scientists identify a new pathway through which HIV can disturb the function of uninfected cells, leading to a sudden decline in immune function. The research suggests that blocking HIV binding to CXCR4 could stop advanced AIDS progression in patients with certain strains of the virus.
The Emory/Atlanta CFAR is a multidisciplinary research center focusing on the prevention and treatment of HIV/AIDS. With a $2.3 million grant, it aims to foster collaboration among diverse HIV/AIDS programs in Atlanta.
A recent study published in Annals of Internal Medicine found that testosterone administration significantly increases lean body mass and improves the quality of life in men with AIDS wasting syndrome. The treatment was shown to produce significant term benefits, making it an important new therapy for patients with this condition.
Researchers investigated enteral supplements' impact on AIDS patients, finding net increases in protein and energy intakes. However, fat-free mass did not increase for the group as a whole, but was inversely correlated with baseline synthesis of fat.
A new study by University of California San Francisco researchers proposes expanding federal Medicaid coverage of HIV drugs to control the disease. The expansion would result in 9,600 more years of life for persons with HIV disease over five-years and prevent 4,200 deaths.
Researchers found that 11% of infected men were long-term nonprogressors at 10 years, but only 2% remained nonprogressors after 18 years. High plasma viral loads are a strong predictor of disease progression. Antiviral therapy is recommended for individuals with rising virus levels and high CD4 counts.
A new vaginal microbicide, BufferGel, has shown promising results in a Phase I study, with 27 women reporting no serious side effects. The gel works by reducing the vaginal pH level, making it an effective barrier to HIV transmission.
The updated guidelines advocate for early, potent combination antiretroviral therapies to prevent AIDS in individuals infected with HIV. The new recommendations suggest that simpler drug regimens may offer greater compliance and convenience.
A study of Rhode Island's needle exchange program found that sharers reuse needles an average of 24 times, contributing to high HIV infection rates; providing clean needles is seen as the single most effective way to prevent its spread.
A major HIV prevention trial involving low-income women and men living in urban areas found that behavioral interventions can reduce HIV-related sexual risk. The study, which recruited 3,700 participants, showed significant improvements in condom use and reductions in unprotected sexual acts after a one-year intervention.
A new study found that social disruption in monkeys infected with simian AIDS virus accelerates disease progression. Monkeys separated from familiar companions experienced faster development of AIDS, highlighting the impact of psychosocial factors on immunodeficiency disease.
Researchers have created a laboratory model of AIDS by infecting tonsil tissue with HIV. The model reveals that changes in the virus's properties lead to immune system deterioration and supports the idea that environmental factors contribute to AIDS development.
Researchers found a significant association between clinic experience and survival of women with AIDS, with 71% of patients in high-experience clinics surviving 21 months after diagnosis. The study suggests that physicians who treat a certain illness more frequently may do it better, especially in HIV management.
A novel diagnostic technique uses isotope mass spectrometry to measure T cell proliferation rates in AIDS patients, allowing physicians to establish the proper time for medication and optimal treatment. The technology holds promise for optimizing AIDS therapy and diagnosing other conditions.
Researchers at UC Berkeley and UC San Francisco have developed a diagnostic technique that measures T-cell production rates in patients with AIDS. The study found that potent protease inhibitor treatments can increase T-cell production, suggesting new treatment options for patients.
Researchers have developed a new diagnostic technique to measure T cell proliferation rates in AIDS patients, revealing that the body's capacity to form new cells is key to T cell counts. The technique allows for personalized treatment optimization and real-time disease monitoring.
A national survey by MTV and Yale University finds that nearly 9 out of 10 young people (87%) believe they are invulnerable to getting the AIDS virus, despite high-risk behaviors such as unprotected sex. The study highlights a need for accurate health information and education, particularly among marginalized groups.
Researchers found that combining ganciclovir eye implants with oral ganciclovir reduces the risk of new CMV disease, Kaposi's sarcoma, and extraocular complications in AIDS patients. The study also showed a delay in median survival time among those receiving combined therapy.
Researchers develop novel approach to block HIV virus from invading white blood cells, potentially treating AIDS patients with genetic modification and reinfusion of immune-boosting lymphocytes. This strategy may provide a new paradigm for HIV treatment, protecting cells from infection rather than inhibiting replication.
Researchers have discovered that HIV can invade cells within any female reproductive tract organ, increasing the risk of infection. The study's findings suggest that vaccine development and disease prevention should aim to confer protection throughout the entire tract.
Scientists at Johns Hopkins Medicine report a test that counts AIDS viruses in blood can identify infected infants and extend their lives by starting treatment early. The test shows within a month after birth whether a baby born to an HIV-positive mother is also infected, allowing for prompt intervention.
Researchers have found that cidofovir, a new antiviral drug, can slow the progression of cytomegalovirus (CMV) retinitis, a common cause of vision loss and blindness in AIDS patients. The study showed that both low and high doses of the drug were effective, allowing for less frequent treatment compared to traditional options.
Researchers found a three-drug combination of indinavir, zidovudine, and lamivudine significantly reduces AIDS symptoms and prolongs patient survival compared to two-drug combinations. The study enrolled 1,156 participants and showed a 45% reduction in disease progression events.
The new Moore Options program uses AIDS specialists as primary care providers and coordinators, focusing on complex patient needs. Published studies show improved outcomes and lower costs for patients treated by experienced care providers.
Researchers at Johns Hopkins Medicine discovered a link between nitric oxide levels and the severity of AIDS dementia. The study found that high levels of nitric oxide synthase in the brains of patients with advanced HIV infection led to brain cell destruction, affecting 20% of those affected.
Emory University researchers identified a subpopulation of HIV-infected infants with a thymic-defect profile, characterized by low CD4+ and CD8+ T cell counts. These high-risk infants were found to develop AIDS symptoms sooner and have increased mortality rates compared to those without the profile.